Pfizer’s breast cancer therapy Palbociclib, better known as Ibrance, is likely to receive insurance coverage.

The Pharmaceutical Benefits Committee of Health Insurance Review & Assessment Service (HIRA)_{건강보험심사평가원} Thursday concluded the Ibrance Cap is appropriate to receive insurance benefits.

If Palbociclib passes a drug price negotiation between the pharmaceutical company and National Health Insurance Service(NHIS)_{국민건강보험공단}, it can get insurance coverage when people take the drug with Letrozole (a product name: Femara Tab.) as the first endocrine therapy.

Before announcing the result of the assessment, a group of breast cancer patients has called for the government and Pfizer to provide insurance benefits for Palbociclib.

The committee also made a similar judgment for melanoma treatment Mekinist Tab. made by Novartis when taken together with Dabrafenib (a product name: Tafinlar Cap).

Meanwhile, lung cancer therapy made by Roche Korea_한국로슈, Alecensa (compound: alectinib), diabetics therapy made by Novo Nordisk Pharma_{노보노디스크}, Victoza Pen Inj, and hepatitis B treatment made by Ildong Pharmaceutical_일동제약, Besivo Tab., received conditional insurance coverage.

The committee evaluated six substances submitted by five pharmaceutical companies.